Afendulis, C. C., Y. He, A. M. Zaslavsky, and M. E. Chernew. 2011. “The Impact of Medicare Part D on Hospitalization Rates.” Health Services Research 46 (4): 1022–1038.Web of SciencePubMedCrossrefGoogle Scholar
Bils, M. 2004. “Measuring the Growth from Better and Better Goods,” NBER working paper no. 10606, July.Google Scholar
Bresnahan, T. F., and R. J. Gordon. 1996. The Economics of New Goods. Chicago: University of Chicago Press.Google Scholar
Briesacher, B. A., Y. Zhao, J. M. Madden, F. Zhang, A. S. Adams, J. Tjia, D. Ross-Degnan, J. H. Gurwitz, and S. B. Soumerai. 2011. “Medicare Part D and Changes in Prescription Drug Use and Cost Burden.” Medical Care 49 (9): 834–841.CrossrefPubMedWeb of ScienceGoogle Scholar
Centers for Medicare & Medicaid Services. 2017. “National Health Expenditure Data – Historical.”Google Scholar
Centre National Hospitalier d’Information sur le Médicament. 2017. “Thériaque Database.”Google Scholar
Congressional Budget Office. 2012. “Offsetting Effects of Prescription Drug Use on Medicare’s Spending for Medical Services,” November.Google Scholar
Danzon, P. M., Y. R. Wang, and L. Wang. 2005. “The Impact of Price Regulation on the Launch Delay of New Drugs – Evidence from Twenty-Five Major Markets in the 1990s.” Health Economics 14 (3): 269–292.PubMedCrossrefGoogle Scholar
Gaynor, M., J. Li, and W. B. Vogt. 2007. “Substitution, Spending Offsets, and Prescription Drug Benefit Design.” Forum for Health Economics and Policy 10 (2): 1–31.Google Scholar
Goldman, D. P., G. F. Joyce, and Y. Zheng. 2007. “Prescription Drug Cost Sharing: Associations with Medication and Medical Utilizations and Spending and Health.” Journal of the American Medical Association 298 (1): 61–69.CrossrefGoogle Scholar
Grossman, Gene M., and Elhanan Helpman. 1993. Innovation and Growth in the Global Economy. Cambridge: MIT Press.Google Scholar
Hsu, J., M. Price, J. Huang, R. Brand, V. Fung, R. Hui, B. Fireman, J. P. Newhouse, and J. V. Selby. 2006. “Unintended Consequences of Caps on Medicare Drug Benefits.” New England Journal of Medicine 354 (22): 2349–2359.CrossrefGoogle Scholar
International Agency for Research on Cancer. 2018. Cancer today, http://gco.iarc.fr/today/home.
Kamal, R., and C. Cox. 2018. “How do Healthcare Prices and use in the U.S. Compare to Other Countries?,” https://www.healthsystemtracker.org/chart-collection/how-do-healthcare-prices-and-use-in-the-u-s-compare-to-other-countries/.
Lichtenberg, F. R. 2009a. “Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence from Longitudinal Country-Level Data on 20 OECD Countries, 1995–2003.” Health Economics 18: 519–534.Web of ScienceCrossrefGoogle Scholar
Lichtenberg, F. R. 2009b. “Home or Nursing Home? The Effect of Medical Innovation on the Demand for Long-Term Care.” In The Economics of New Health Technologies: Incentives, Organization, and Financing, edited by J. Costa-Font, C. Courbage, and A. McGuire. Oxford: Oxford University Press.Google Scholar
Lichtenberg, F. R. 2014a. “The Impact of Pharmaceutical Innovation on Disability Days and the Use of Medical Services in the United States, 1997–2010.” Journal of Human Capital 8 (4): 432–480.Web of ScienceCrossrefGoogle Scholar
Lichtenberg, F. R. 2017. “The Impact of Pharmaceutical Innovation on Premature Mortality, Hospital Separations, and Cancer Survival in Australia.” Economic Record 93 (302): 353–378.Web of ScienceCrossrefGoogle Scholar
Lichtenberg, F. R. 2018. “The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries.” Journal of Demographic Economics 84: 309–354.CrossrefWeb of ScienceGoogle Scholar
McWilliams, J. M., A. M. Zaslavsky, and H. A. Huskamp. 2011. “Implementation of Medicare Part D and Nondrug Medical Spending for Elderly Adults with Limited Prior Drug Coverage.” Journal of the American Medical Association 306 (4): 402–409.Web of ScienceCrossrefGoogle Scholar
National Cancer Institute. 2018. Enhancing Drug Discovery and Development, https://www.cancer.gov/research/areas/treatment/enhancing-drug-discovery.
OECD. 2017a. OECD Health Statistics 2017, Definitions, Sources and Methods, Hospital discharges by diagnostic categories.Google Scholar
OECD. 2017b. OECD Health Statistics database.Google Scholar
OECD. 2017c. International shortlist for hospital morbidity tabulation.Google Scholar
Sampat, B., and F. R. Lichtenberg. 2011. “What are the Respective Roles of the Public and Private Sectors in Pharmaceutical Innovation?.” Health Affairs 30 (2): 332–339.Web of ScienceCrossrefGoogle Scholar
About the article
Published Online: 2019-04-24
Funding Source: National Institute on Aging
Award identifier / Grant number: R24 AG048059
National Institute on Aging, Pfizer, and PhRMA, Funder Id: http://dx.doi.org/10.13039/100000049, Grant Number: R24 AG048059.